Indiana Ups State Power To Limit Pseudoephedrine Product Sales
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
DEA has the authority and expertise to conduct stress tests on pseudoephedrine formulations, says CHPA state government director Carol Gutierrez. But Indiana allows its pharmacy board to say whether a PSE product is tamper-resistant.
You may also be interested in...
Perrigo Deal Makes Extraction-Resistant PSE A Two-Player Competition
Via Highland Pharmaceuticals agreement, Perrigo snaps up the only tamper-resistant pseudoephedrine formulation still available for licensing. It now goes up against Bayer – but will beat the pharma giant to market.
Tamper-Resistant PSE Takes Big Pharma Stage: Bayer Licenses Acura’s Formulation
Bayer gains exclusive worldwide license to Acura Pharmaceuticals’ Impede technology for use in a pseudoephedrine-containing product resistant to extraction to make methamphetamine. The deal is Acura’s first licensing, and the first move toward tamper-resistant PSE by a major pharma firm.
To Curb PSE Diversion, Retailers Lead By Example With Emphasis On Tamper-Resistant Products
An HHS agency’s 2013 drug use survey shows the number of meth users rising by 155,000 after changing little the previous two years. Acura Pharmaceuticals notes the survey and Tennessee data showing that making only tamper-resistant, single-ingredient PSE products available affects the diversion rate.